Methods for Enhancing Polygenic Risk Prediction Models for Complex Disease
Methods for Enhancing Polygenic Risk Prediction Models for Complex Disease
批准号:
10717244
负责人:
Dokyoon Kim
金额:
$80.48万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-07-01 至 2027-04-30
关键词:
AddressAdoptedAfrican ancestryAreaAtrial FibrillationCardiomyopathiesCardiovascular DiseasesCardiovascular systemClinicalComplexCoronary ArteriosclerosisDNADataDevelopmentDiseaseEarly DiagnosisEarly identificationElectronic Health RecordElectronic Medical Records and Genomics NetworkEmerging TechnologiesEuropean ancestryGeneticGenetic Predisposition to DiseaseGenetic RiskGenomeGoalsHealth PersonnelHeart failureIncidenceIndividualInformaticsInvestigationLifeMachine LearningMathematicsMedicineMethodsModelingMorbidity - disease ratePhenotypePrecision HealthPreventionPrevention strategyPreventive therapyPublic HealthResearchRiskRisk FactorsScoring MethodSurveysTestingTranslatingTranslationsVariantVascular DiseasesVeteransbiobankcardiac muscle diseasecardiovascular disorder riskcardiovascular risk factorclinical careclinical decision supportclinical implementationclinical riskcohortdata integrationdeep learning modeldesigndisorder preventiondisorder riskearly screeningeffective therapyexomegenetic informationgenetic risk factorgenetic variantgenome-wideheart rhythmhigh risk populationimprovedinnovationmachine learning methodmortalitynon-geneticnovelpolygenic risk scorepredictive modelingpressureprogramsprototyperare variantresponserisk predictionrisk prediction modelsocialsocial health determinantsstatisticstraittranslational impacttranslational potentialwhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Early screening and prevention of individuals at risk of complex diseases are important strategies for reducing
morbidity and mortality. Polygenic risk scores (PRS) are the cumulative, mathematical aggregation of risk derived
from the contributions of many DNA variants across the genome. PRS are an emerging technology in the field
of disease risk prediction and have been shown to be correlated with disease incidence. While PRS have shown
great promise for complex diseases, current PRS models are overly simplistic and have limited predictive power
and clinical utility. PRS do not account for the effects of rare genetic variants or other risk factors (clinical,
environmental, social determinants of health) on disease risk. Rare variants generally have greater effects on
disease risk due to selective pressure, but only a small number of individuals carry any single rare variant. The
sparsity of rare variants makes it difficult to directly incorporate them into PRS. Additionally, while it is known that
clinical, environmental, and social risk factors also influence risk, few analyses have successfully integrated PRS
with these important non-genetic factors.
To address this issue, we will develop novel translational informatics methods that integrate clinical,
environmental, and genetic data to improve disease risk prediction. We will assess the clinical utility of these
integrated risk prediction models using cardiovascular disease (CVD) to evaluate the potential for translation to
clinical use. Based on the complexity of CVD, we hypothesize that a comprehensive range of risk factors along
with rare variants need to be incorporated into PRS to improve the risk prediction and maximize the clinical utility
of PRS for CVD.
To achieve our goal, our specific aims are: 1) To develop novel methods that incorporate rare genetic variants
into Polygenic Risk Scores (PRS); 2) To evaluate Integrated Risk Models that combine clinical, environmental,
and social risk factors with PRS; 3) To develop and evaluate deep learning models integrating genetic, clinical,
environmental, and social risk factors; 4) To translate our integrated models into the electronic health record
(EHR). If these specific aims are achieved, we will have a set of integrated models that can be used in
downstream clinical implementation programs to ultimately have a translational impact on disease treatment and
prevention. Using these novel computational risk prediction models for precision health, along with our EHR
integration approaches, will allow for the translation of integrated risk prediction into routine clinical care.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Translational big data analytic approaches to advance drug repurposing for Alzheimer's disease
-
批准号:10175930
-
项目类别:
-
资助金额:$80.92万
-
财政年份:2021
-
负责人:Dokyoon Kim
-
依托单位:
Translational big data analytic approaches to advance drug repurposing for Alzheimer's disease
-
批准号:10405522
-
项目类别:
-
资助金额:$77.79万
-
财政年份:2021
-
负责人:Dokyoon Kim
-
依托单位:
Translational big data analytic approaches to advance drug repurposing for Alzheimer's disease
-
批准号:10613975
-
项目类别:
-
资助金额:$76.16万
-
财政年份:2021
-
负责人:Dokyoon Kim
-
依托单位:
Unravelling genetic basis of comorbidity using EHR-linked biobank data
-
批准号:10224747
-
项目类别:
-
资助金额:$47.94万
-
财政年份:2020
-
负责人:Dokyoon Kim
-
依托单位:
Unravelling genetic basis of comorbidity using EHR-linked biobank data
-
批准号:10034691
-
项目类别:
-
资助金额:$48.61万
-
财政年份:2020
-
负责人:Dokyoon Kim
-
依托单位:
Unravelling genetic basis of comorbidity using EHR-linked biobank data
-
批准号:10687123
-
项目类别:
-
资助金额:$47.5万
-
财政年份:2020
-
负责人:Dokyoon Kim
-
依托单位:
Unravelling genetic basis of comorbidity using EHR-linked biobank data
-
批准号:10460229
-
项目类别:
-
资助金额:$47.5万
-
财政年份:2020
-
负责人:Dokyoon Kim
-
依托单位:
Unravelling genetic basis of comorbidity using EHR-linked biobank data
-
批准号:10372247
-
项目类别:
-
资助金额:$32.5万
-
财政年份:2020
-
负责人:Dokyoon Kim
-
依托单位:
Integrating Neuroimaging, Multi-omics, and Clinical Data in Complex Disease
-
批准号:9916801
-
项目类别:
-
资助金额:$34.15万
-
财政年份:2017
-
负责人:Dokyoon Kim
-
依托单位:
Integrating Neuroimaging, Multi-omics, and Clinical Data in Complex Disease
-
批准号:9287487
-
项目类别:
-
资助金额:$36.71万
-
财政年份:2017
-
负责人:Dokyoon Kim
-
依托单位:
海外基金